Bladder Cancer, Chemotherapy Effect
Conditions
Keywords
neoadjuvant chemotherapy, cisplatine
Brief summary
Determine the sensitivity/resistance to chemotherapy of the various subgroups of muscle-invasive bladder cancers, including the basal subgroup (about 25% of these tumours) according to 4 different classifications based on molecular or immunohistochemical classifiers.
Interventions
COMBINATION_PRODUCTneoadjuvant chemotherapy with cisplatine
Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
Sponsors
Institut Curie
APHP
University Hospital, Rouen
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
of Patients enrolled in VESPER study: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort and : * having signed an informed consent form for the participation to the collection or * dead/lost to follow-up without prior opposition expressed against research program, * genetic analysis will only be carried out for patients who have signed the genetic consent form. Inclusion Criteria of Patients from St Louis cohort not enrolled in VESPER study: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort and : * having received an informed form for the participation to the collection and not having expressed opposition against research program within 1 month or * dead/lost to follow-up without prior opposition expressed against research program,
Exclusion criteria
-Patients enrolled in VESPER study:Tumors from patient having withdrawn his/her informed consent form for the participation to the collection and/or VESPER project. OR -Patients from St Louis not enrolled in VESPER study:Tumors from patient having expressed opposition against research program after 1 month for the participation to the collection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identifying molecular subgroups of bladder cancer patients within VESPER and Saint-Louis cohort, who could benefit from neoadjuvant chemotherapy, taking into account the existence of different classification systems. | through study completion, an average of 3 years |
| Determining which classification(s) has(ve) the best ability to identifying subgroups of tumours sensitive or resistant to neoadjuvant chemotherapy. | through study completion, an average of 3 years |
| Identifying mechanisms of resistance in basal subgroups. | through study completion, an average of 3 years |
Countries
France
Outcome results
None listed